Prognostic value of expression of kit67, p53, topoiiα and GSTP1 for curatively resected advanced gastric cancer patients receiving adjuvant paclitaxel plus capecitabine chemotherapy

Hepato-Gastroenterology

Volumn 59, Issue 117, 2012, Pages 1327-1332

  Zha, Yong ^a   Cun, Yingli ^a   Zhang, Qi ^a   Li, Yong ^a   Tan, Jing ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Adjuvant chemotherapy; Gastric cancer; p53; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; DEXAMETHASONE; DIPHENHYDRAMINE; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTATHIONE TRANSFERASE P1; GRANULOCYTE COLONY STIMULATING FACTOR; KI 67 ANTIGEN; PACLITAXEL; PROTEIN P53; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTRECTOMY; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERSENSITIVITY REACTION; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK FACTOR; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; TOTAL STOMACH RESECTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DNA TOPOISOMERASES, TYPE II; FEMALE; FLUOROURACIL; GASTRECTOMY; GLUTATHIONE TRANSFERASE; HUMANS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PACLITAXEL; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84865165593     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12204     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, et al.: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Sasako M, Sano T, Yamamoto S, et al.: D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359:453-462.
3. Zhan WH, Zhang ZD, He YL, Zhou X: Cox regression analysis of factors influencing postoperative survival rate of gastric cancer patients. Chin J Bases Clin General Surg 2006; 13:29-37.
4. Zhang H, Liu C, Wu D, Meng Y, Song R, Lu P, Wang S: Does D3 surgery offer a better survival outcome compared to D1 surgery for gastric cancer? A result based on a hospital population of two decades as taking D2 surgery for reference. BMC Cancer 2010; 10:308.
5. Bang YJ, Kim YW, Yang HK, et al.: Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012; 379:315-321.
6. Patel SH, Kooby DA: Gastric adenocarcinoma surgery and adjuvant therapy. Surg Clin North Am 2011; 91:1039-1077.
7. Baize N, Abakar-Mahamat A, Mounier N, et al.: Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. Cancer Chemother Pharmacol 2009; 64:549-555.
8. Kang HJ, Chang HM, Kim TW, et al.: A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer. Br J Cancer 2008; 98:316-322.
9. Sakurai Y, Yoshida I, Kamoshida S, et al.: Changes of gene expression of thymidine Phosphorylase, thymidylate synthase, dihydropyrimidine dehydrogenase after the administration of 5′-deoxy-5-fluorouridine, paclitaxel and its combination in human gastric cancer xenografts. Anticancer Res 2008; 28:1593-1602.
10. Kim YJ, Kim MA, Im SA, et al.: Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer. Cancer Invest 2008; 26:152-158.
11. Gao J, Lu M, Yu JW, Li YY, Shen L: Thymidine phosphorylase/b-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel. BMC Cancer 2011; 11:177.
12. Nishida T: Adjuvant therapy for gastric cancer after D2 gastrectomy. Lancet 2012; 379:315-321.
13. Tzanakis NE, Peros G, Karakitsos P, et al.: Prognostic significance of p53 and Ki67 proteins expression in Greek gastric cancer patients. Acta Chir Belg 2009; 109:606-611.
14. Chen L, Li X, Wang GL, Wang Y, Zhu YY, Zhu J: Clinicopathological significance of over-expression of TSPAN1, Ki67 and CD34 in gastric carcinoma. Tumori 2008; 94:531-538.
15. Oshima CT, Iriya K, Forones NM: Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma 2005; 52:420-424.
16. Shomori K, Nishihara K, Tamura T, et al.: Geminin, Ki67, and mini-chromosome maintenance 2 in gastric hyperplastic polyps, adenomas, and intestinal-type carcinomas: pathobiological significance. Gastric Cancer 2010; 13:177-185.
17. Liu X, Cai H, Huang H, Long Z, Shi Y, Wang Y: The prognostic significance of apoptosis-related biological markers in Chinese gastric cancer patients. PLoS One 2011; 6:e29670.
18. Deveci MS, Deveci G: Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer 2007; 10:112-116.
19. Satomi D, Takiguchi N, Koda K, et al.: Apoptosis and apoptosis-associated gene products related to the response to neoadjuvant chemotherapy for gastric cancer. Int J Oncol 2002; 20:1167-1171.
20. Matsuhashi N, Saio M, Matsuo A, Sugiyama Y, Saji S: Expression of p53 protein as a predictor of the response to 5-fluorouracil and cisplatin chemotherapy in human gastrointestinal cancer cell lines evaluated with apoptosis by use of thin layer collagen gel. Int J Oncol 2004; 24:807-813.
21. Kamoshida S, Suzuki M, Shimomura R, et al.: Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer. Br J Cancer 2007; 96:277-283.
22. Errington F, Wilimore E, Leontiou C, Tilby MJ, Austin CA: Differences in the longevity of topoIIa and topoIIb drug-stabilized cleavable complexes and the relationship to drug sensitivity. Cancer Chemother Pharmacol 2004; 53:155-162.
23. Koshiyama M, Fujii H, Kinezaki M, Yoshida M: Correlation between Topo II alpha expression and chemosensitivity testing for TopoII-targeting drugs in gynecological carcinomas. Anticancer Res 2001; 21:905-910.
24. Cornarotti M, Capranico G, Bohm S, et al.: Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Int J Cancer 1996; 67:479-484.
25. Vranic S, Frkovic-Grazio S, Lamovec J, et al.: Adenoid cystic carcinomas of the breast have low TopoIIα expression but frequently over-express EGFR protein without EGFR gene amplification. Hum Pathol 2010; 41:1617-1623.
26. Kim KH, Kwon HC, Oh SY, et al.: Clinicopathological significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advancedgastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy. Biomarkers 2011; 16:74-82.
27. Wang X, Pavelic ZP, Li Y, et al.: Over-expression and amplification of glutathione S-transferase pi gene in head and neck squamous cell carcinomas. Clin Cancer Res 1997; 3:111-114.
28. Satta T, Isobe K, Yamauchi M, Nakashima I, Takagi H: Expression of MDR1 and glutathione S transferase-pi genes and chemo-sensitivities in human gastrointestinal cancer. Cancer 1992; 69:941-946.
29. Economopoulos KP, Sergentanis TN, Vlahos NF: Glutathione S-transferase M1, T1, and P1 polymorphisms and ovarian cancer risk: a meta-analysis. Int J Gynecol Cancer 2010; 20:732-737.
30. Kwon HC, Roh MS, Oh SY, et al.: Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/ oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 2007; 18:504-509.